{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:25:14Z","timestamp":1760783114362},"reference-count":146,"publisher":"Oxford University Press (OUP)","issue":"1006","license":[{"start":{"date-parts":[[2009,7,23]],"date-time":"2009-07-23T00:00:00Z","timestamp":1248307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The inflammatory neuropathies are a large diverse group of immune-mediated neuropathies that are amenable to treatment and may be reversible. Their accurate diagnosis is essential for informing the patient of the likely course and prognosis of the disease, informing the treating physician of the appropriate therapy and informing the scientific community of the results of well-targeted, designed and performed clinical trials. With the advent of biological therapies able to manipulate the immune response more specifically, an understanding of the pathogenesis of these conditions is increasingly important. This review presents a broad overview of the pathogenesis, diagnosis and therapy of inflammatory neuropathies, concentrating on the most commonly encountered conditions.<\/jats:p>","DOI":"10.1136\/jnnp.2008.158303","type":"journal-article","created":{"date-parts":[[2009,2,19]],"date-time":"2009-02-19T18:28:53Z","timestamp":1235068133000},"page":"437-446","source":"Crossref","is-referenced-by-count":5,"title":["Diagnosis and treatment in inflammatory neuropathies"],"prefix":"10.1093","volume":"85","author":[{"given":"M P T","family":"Lunn","sequence":"first","affiliation":[{"name":"Centre for Neuromuscular Disease, National Hospital for Neurology and Neurosurgery , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H J","family":"Willison","sequence":"additional","affiliation":[{"name":"Division of Clinical Neurosciences, Southern General Hospital , Glasgow , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2009,7,23]]},"reference":[{"key":"2023041909290491300_b1","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1212\/WNL.53.9.2113","article-title":"Microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy","volume":"53","author":"Dyck","year":"1999","journal-title":"Neurology"},{"key":"2023041909290491300_b2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.5414\/NPP27096","article-title":"Sarcoid neuropathy: clinico-pathological study of 4 new cases and review of the literature","volume":"27","author":"Vital","year":"2008","journal-title":"Clin.Neuropathol"},{"key":"2023041909290491300_b3","first-page":"CD006828","article-title":"Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome","author":"Kuwabara","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2023041909290491300_b4","first-page":"1462","article-title":"Sur un syndrome de radiculo-n\u00e9vrite avec hyperalbuminose du liquide cephalorachidien sans r\u00e9action cellulaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineux","volume":"40","author":"Guillain","year":"1916","journal-title":"Bull Soc M\u00e9d H\u00f4p Paris"},{"key":"2023041909290491300_b5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1600-0404.2006.00731.x","article-title":"Guillain\u2013Barr\u00e9 syndrome in northwest Greece","volume":"115","author":"Markoula","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"2023041909290491300_b6","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s100720200036","article-title":"Validity of hospital discharge diagnoses for public health surveillance of the Guillain\u2013Barr\u00e9 syndrome","volume":"23","author":"Bogliun","year":"2002","journal-title":"Neurol Sci"},{"key":"2023041909290491300_b7","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1212\/01.wnl.0000310983.38724.d4","article-title":"Guillain\u2013Barr\u00e9 syndrome: incidence and mortality rates in US hospitals","volume":"70","author":"Alshekhlee","year":"2008","journal-title":"Neurology"},{"key":"2023041909290491300_b8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/ana.410330402","article-title":"Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China","volume":"33","author":"McKhann","year":"1993","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b9","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2007.03.006","article-title":"Impact of late-onset Pompe disease on participation in daily life activities: Evaluation of the Rotterdam Handicap Scale","author":"Hagemans","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"2023041909290491300_b10","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ana.410440512","article-title":"Electrophysiological classification of Guillain\u2013Barr\u00e9 syndrome: clinical associations and outcome. Plasma Exchange\/Sandoglobulin Guillain\u2013Barr\u00e9 Syndrome Trial Group","volume":"44","author":"Hadden","year":"1998","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b11","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1212\/WNL.53.3.598","article-title":"Prognostic factors of Guillain\u2013Barr\u00e9 syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain\u2013Barr\u00e9 Study Group","volume":"53","author":"Visser","year":"1999","journal-title":"Neurology"},{"key":"2023041909290491300_b12","first-page":"444","article-title":"The sural sensory action potential in Guillain\u2013Barr\u00e9 syndrome","volume":"3","author":"Murray","year":"1980","journal-title":"Muscle Nerve"},{"key":"2023041909290491300_b13","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1212\/WNL.43.10.1911","article-title":"Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain\u2013Barr\u00e9 syndrome: clinical and immunohistochemical studies","volume":"43","author":"Chiba","year":"1993","journal-title":"Neurology"},{"key":"2023041909290491300_b14","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/1531-8249(199902)45:2<168::AID-ANA6>3.0.CO;2-6","article-title":"Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain\u2013Barr\u00e9 syndrome","volume":"45","author":"Ho","year":"1999","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b15","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/ana.410380516","article-title":"Anti-ganglioside GM1 antibodies in Guillain\u2013Barr\u00e9 syndrome and their relationship to Campylobacter jejuni infection","volume":"38","author":"Rees","year":"1995","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ncpneuro0452","article-title":"From bench to bedside\u2014experimental rationale for immune-specific therapies in the inflamed peripheral nerve","volume":"3","author":"Meyer zu","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"2023041909290491300_b17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/jnnp.64.1.74","article-title":"Epidemiological study of Guillain\u2013Barr\u00e9 syndrome in south east England","volume":"64","author":"Rees","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909290491300_b18","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1191\/0269215505cr918oa","article-title":"Disability and health-related quality of life in Guillain\u2013Barr\u00e9 syndrome during the first two years after onset: a prospective study","volume":"19","author":"Forsberg","year":"2005","journal-title":"Clin Rehabil"},{"key":"2023041909290491300_b19","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1001\/archneur.62.8.1194","article-title":"Supportive care for patients with Guillain\u2013Barr\u00e9 syndrome","volume":"62","author":"Hughes","year":"2005","journal-title":"Arch Neurol"},{"key":"2023041909290491300_b20","first-page":"CD001446","article-title":"Corticosteroids for Guillain\u2013Barr\u00e9 syndrome","author":"Hughes","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2023041909290491300_b21","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0140-6736(78)91837-8","article-title":"Treatment of acute polyneuropathy by plasma exchange","volume":"2","author":"Brettle","year":"1978","journal-title":"Lancet"},{"key":"2023041909290491300_b22","first-page":"15","article-title":"Cellular aspect of neuroinflammation in Guillain\u2013Barr\u00e9 syndrome: a key to a new therapeutic option?","volume":"158","author":"Creange","year":"2002","journal-title":"Rev Neurol (Paris)"},{"key":"2023041909290491300_b23","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ana.410220612","article-title":"Efficiency of plasma exchange in Guillain\u2013Barr\u00e9 syndrome: role of replacement fluids","volume":"22","author":"French Cooperative Group on Plasma Exchange in Guillain\u2013Barr\u00e9 syndrome","year":"1987","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b24","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/ana.410410304","article-title":"Appropriate number of plasma exchanges in Guillain\u2013Barr\u00e9 syndrome","volume":"41","author":"The French Cooperative Group on Plasma Exchange in Guillain\u2013Barr\u00e9 Syndrome","year":"1997","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b25","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.38.10.1639","article-title":"Treatment of Guillain\u2013Barr\u00e9 syndrome with high-dose gammaglobulin","volume":"38","author":"Kleyweg","year":"1988","journal-title":"Neurology"},{"key":"2023041909290491300_b26","first-page":"CD002063","article-title":"Intravenous immunoglobulin for Guillain\u2013Barr\u00e9 syndrome","author":"Hughes","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2023041909290491300_b27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/brain\/awh328","article-title":"Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide","volume":"128","author":"Bechtold","year":"2005","journal-title":"Brain"},{"key":"2023041909290491300_b28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/ana.20546","article-title":"Complement inhibition abrogates nerve terminal injury in Miller Fisher syndrome","volume":"58","author":"Halstead","year":"2005","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b29","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awm316","article-title":"Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model","volume":"131","author":"Halstead","year":"2008","journal-title":"Brain"},{"key":"2023041909290491300_b30","doi-asserted-by":"crossref","first-page":"8292","DOI":"10.1074\/jbc.M609858200","article-title":"In vivo characterization and therapeutic efficacy of a C5-specific inhibitor from the soft tick Ornithodoros moubata","volume":"282","author":"Hepburn","year":"2007","journal-title":"J Biol Chem"},{"key":"2023041909290491300_b31","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"key":"2023041909290491300_b32","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1085-9489.2005.10302.x","article-title":"Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society","volume":"10","author":"European Federation of Neurological Societies\/Peripheral Nerve Society Guideline* on management of chronic inflammatory demyelinating polyradiculoneuropathy","year":"2005","journal-title":"J Peripher Nerv Syst"},{"issue":"(1 Suppl)","key":"2023041909290491300_b33","first-page":"176","article-title":"Prevalence and morbidity of chronic inflammatory neuropathies in South East England","volume":"13","author":"Mahdi-Rogers","year":"2008","journal-title":"J Peripher Nerv Syst"},{"issue":"(1 Suppl)","key":"2023041909290491300_b34","first-page":"46","article-title":"Development of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy","volume":"12","author":"Koski","year":"2007","journal-title":"J Peripher Nerv Syst"},{"key":"2023041909290491300_b35","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1212\/01.wnl.0000260972.07422.ea","article-title":"Classifications and treatment responses in chronic immune-mediated demyelinating polyneuropathy","volume":"68","author":"Tackenberg","year":"2007","journal-title":"Neurology"},{"key":"2023041909290491300_b36","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/00005792-196905000-00001","article-title":"The inflammatory lesion in idiopathic polyneuritis","volume":"48","author":"Asbury","year":"1969","journal-title":"Medicine"},{"key":"2023041909290491300_b37","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1084\/jem.194.5.677","article-title":"Development of spontaneous autoimmune peripheral polyneuropathy in B7-2-deficient NOD mice","volume":"194","author":"Salomon","year":"2001","journal-title":"J Exp Med"},{"key":"2023041909290491300_b38","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/1531-8249(200006)47:6<765::AID-ANA9>3.0.CO;2-8","article-title":"Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients","volume":"47","author":"Yan","year":"2000","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b39","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1007\/s004150200072","article-title":"Gamma delta T cells infiltrating sensory nerve biopsies from patients with inflammatory neuropathy","volume":"249","author":"Winer","year":"2002","journal-title":"J Neurol"},{"key":"2023041909290491300_b40","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1136\/jnnp.69.3.362","article-title":"Enhanced B7 costimulatory molecule expression in inflammatory human sural nerve biopsies","volume":"69","author":"Kiefer","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909290491300_b41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1212\/WNL.59.12_suppl_6.S7","article-title":"Immune mechanisms in chronic inflammatory demyelinating neuropathy","volume":"59","author":"Kieseier","year":"2002","journal-title":"Neurology"},{"key":"2023041909290491300_b42","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.410430404","article-title":"Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain\u2013Barr\u00e9 syndrome","volume":"43","author":"Kieseier","year":"1998","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b43","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/jnnp.2003.025692","article-title":"Chronic inflammatory demyelinating polyneuropathy: decreased claudin-5 and relocated ZO-1","volume":"75","author":"Kanda","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909290491300_b44","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/brain\/81.2.157","article-title":"Recurrent polyneuropathies and their corticosteroid treatment","volume":"81","author":"Austin","year":"1958","journal-title":"Brain"},{"key":"2023041909290491300_b45","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/ana.410090719","article-title":"Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment","volume":"9","author":"Dalakas","year":"1981","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b46","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1093\/brain\/110.6.1617","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy. A clinical and electrophysiological study of 92 cases","volume":"110","author":"McCombe","year":"1987","journal-title":"Brain"},{"key":"2023041909290491300_b47","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/archneur.1989.00520440064022","article-title":"Chronic inflammatory demyelinating polyradiculopathy: Clinical characteristics, course, and recommendations for diagnostic criteria","volume":"46","author":"Barohn","year":"1989","journal-title":"Arch Neurol"},{"key":"2023041909290491300_b48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410110205","article-title":"Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment","volume":"11","author":"Dyck","year":"1982","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b49","first-page":"CD002062","article-title":"Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Mehndiratta","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"key":"2023041909290491300_b50","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/jnnp.57.7.778","article-title":"Pure motor demyelinating neuropathy: Deterioration after steroid treatment and improvement with intravenous immunoglobulin","volume":"57","author":"Donaghy","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909290491300_b51","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1474-4422(02)00222-3","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review","volume":"1","author":"Van Schaik","year":"2002","journal-title":"Lancet Neurol"},{"key":"2023041909290491300_b52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"key":"2023041909290491300_b53","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/mus.20909","article-title":"Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy","volume":"37","author":"Lee","year":"2008","journal-title":"Muscle Nerve"},{"key":"2023041909290491300_b54","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(79)90665-2","article-title":"Treatment of chronic relapsing Guillain\u2013Barr\u00e9 syndrome by plasma exchange","volume":"2","author":"Levy","year":"1979","journal-title":"Lancet"},{"key":"2023041909290491300_b55","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/ana.410060313","article-title":"Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange","volume":"6","author":"Server","year":"1979","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b56","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJM198602203140801","article-title":"Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"314","author":"Dyck","year":"1986","journal-title":"N Engl J Med"},{"key":"2023041909290491300_b57","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/brain\/119.4.1055","article-title":"Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"2023041909290491300_b58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b59","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"36","author":"Dyck","year":"1994","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b60","first-page":"CD003280","article-title":"Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Hughes","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"2023041909290491300_b61","first-page":"(1 Suppl)","article-title":"A pilot randomised controlled trial of methotrexate for CIDP: lessons for future trials","volume":"13","author":"Mahdi-Rogers","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"2023041909290491300_b62","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/brain\/118.2.359","article-title":"Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy","volume":"118","author":"Simmons","year":"1995","journal-title":"Brain"},{"key":"2023041909290491300_b63","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1212\/WNL.35.8.1173","article-title":"Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy","volume":"35","author":"Dyck","year":"1985","journal-title":"Neurology"},{"key":"2023041909290491300_b64","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0022-510X(03)00010-8","article-title":"Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy","volume":"210","author":"Chin","year":"2003","journal-title":"J Neurol Sci"},{"key":"2023041909290491300_b65","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1016\/S0041-1345(98)01389-X","article-title":"Positive effects of tacrolimus in a case of CIDP","volume":"30","author":"Ahlmen","year":"1998","journal-title":"Transplant Proc"},{"key":"2023041909290491300_b66","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1212\/01.wnl.0000277266.53449.8b","article-title":"Nonmyeloablative autologous hematopoietic stem cell transplantation for refractory CIDP","volume":"69","author":"Oyama","year":"2007","journal-title":"Neurology"},{"issue":"(1 Suppl)","key":"2023041909290491300_b67","first-page":"55S","article-title":"Autologous peripheral blood progenitor cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"12","author":"Mahdi-Rogers","year":"2007","journal-title":"J Peripher Nerv Syst"},{"key":"2023041909290491300_b68","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1136\/jnnp.2005.076869","article-title":"Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H)","volume":"77","author":"Hirst","year":"2006","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909290491300_b69","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.410240113","article-title":"A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside","volume":"24","author":"Pestronk","year":"1988","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b70","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/(SICI)1097-4598(199704)20:4<479::AID-MUS11>3.0.CO;2-U","article-title":"Muscle hypertrophy in multifocal motor neuropathy is associated with continuous motor unit activity","volume":"20","author":"O\u2019Leary","year":"1997","journal-title":"Muscle Nerve"},{"key":"2023041909290491300_b71","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1468-1331.2006.01466.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy","volume":"13","author":"Van Schaik","year":"2006","journal-title":"Eur J Neurol"},{"key":"2023041909290491300_b72","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/(SICI)1097-4598(200006)23:6<900::AID-MUS9>3.0.CO;2-Y","article-title":"Natural history of 46 patients with multifocal motor neuropathy with conduction block","volume":"23","author":"Taylor","year":"2000","journal-title":"Muscle Nerve"},{"key":"2023041909290491300_b73","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/bbrc.1995.2760","article-title":"Recognition of human recombinant myelin associated glycoprotein by anti-carbohydrate antibodies of the L2\/HNK-1 family","volume":"217","author":"Bigliardi-Qi","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"2023041909290491300_b74","first-page":"CD004429","article-title":"Intravenous immunoglobulin for multifocal motor neuropathy","author":"Van Schaik","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2023041909290491300_b75","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/jnnp.2007.121756","article-title":"Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients","volume":"79","author":"Leger","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909290491300_b76","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1212\/01.wnl.0000277697.55288.d0","article-title":"Multifocal motor neuropathy: the diagnostic spectrum and response to treatment","volume":"69","author":"Slee","year":"2007","journal-title":"Neurology"},{"key":"2023041909290491300_b77","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0035-3787(07)90358-6","article-title":"Long-term follow-up of multifocal motor neuropathy with conduction block under intravenous immunoglobulin","volume":"163","author":"Delmont","year":"2007","journal-title":"Rev Neurol (Paris)"},{"key":"2023041909290491300_b78","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/01.WNL.0000140497.85952.FA","article-title":"Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg","volume":"63","author":"Vucic","year":"2004","journal-title":"Neurology"},{"key":"2023041909290491300_b79","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/01.wco.0000175937.31569.15","article-title":"Multifocal motor neuropathy","volume":"18","author":"Leger","year":"2005","journal-title":"Curr Opin Neurol"},{"key":"2023041909290491300_b80","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1136\/jnnp.63.5.674","article-title":"Intravenous immunoglobulin treatment in lower motor neuron disease associated with highly raised anti-GM1 antibodies","volume":"63","author":"Van den Berg","year":"1997","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909290491300_b81","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jns.2008.02.022","article-title":"The clinical value of therapeutic plasma exchange in multifocal motor neuropathy","volume":"271","author":"Lehmann","year":"2008","journal-title":"J Neurol Sci"},{"key":"2023041909290491300_b82","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0022-510X(97)00312-2","article-title":"Clinical correlate and fine specificity of anti-GQ1b antibodies in peripheral neuropathy","volume":"155","author":"Carpo","year":"1998","journal-title":"J Neurol Sci"},{"key":"2023041909290491300_b83","first-page":"CD003217","article-title":"Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy","author":"Umapathi","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2023041909290491300_b84","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ana.410390308","article-title":"Sensory nerve pathology in multifocal motor neuropathy","volume":"39","author":"Corse","year":"1996","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b85","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/mus.20024","article-title":"Mycophenolate mofetil in dysimmune neuropathies: a preliminary study","volume":"29","author":"Benedetti","year":"2004","journal-title":"Muscle Nerve"},{"key":"2023041909290491300_b86","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/brain\/awm144","article-title":"Mycophenolate mofetil as adjunctive therapy for MMN patients: a randomized, controlled trial","volume":"130","author":"Piepers","year":"2007","journal-title":"Brain"},{"key":"2023041909290491300_b87","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1136\/jnnp.74.4.485","article-title":"Treatment of IgM antibody associated polyneuropathies using rituximab","volume":"74","author":"Pestronk","year":"2003","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909290491300_b88","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1212\/01.WNL.0000098996.02934.86","article-title":"Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab","volume":"61","author":"Rojas-Garcia","year":"2003","journal-title":"Neurology"},{"key":"2023041909290491300_b89","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/mus.20664","article-title":"Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial","volume":"35","author":"Gorson","year":"2007","journal-title":"Muscle Nerve"},{"issue":"(1 Suppl)","key":"2023041909290491300_b90","first-page":"164S","article-title":"An open-label trial of rituximab (rituxan) in multifocal motor neuropathy (MMN)","volume":"13","author":"Chaudhry","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"2023041909290491300_b91","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s00415-003-0131-3","article-title":"Efficacy of cyclosporine treatment in multifocal motor neuropathy","volume":"250","author":"Nemni","year":"2003","journal-title":"J Neurol"},{"key":"2023041909290491300_b92","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/jnnp.66.2.197","article-title":"Chronic motor neuropathies: response to interferon-beta1a after failure of conventional therapies","volume":"66","author":"Martina","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909290491300_b93","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1212\/WNL.54.7.1518","article-title":"Treatment of multifocal motor neuropathy with interferon-beta1A","volume":"54","author":"Van den Berg-Vos","year":"2000","journal-title":"Neurology"},{"issue":"(1 Suppl)","key":"2023041909290491300_b94","first-page":"183S","article-title":"Efficacy and tolerability of oral methotrexate as adjunctive therapy in patients with multifocal motor neuropathy treated with IVIg","volume":"13","author":"Terenghi","year":"2008","journal-title":"J Peripher Nerv Syst"},{"key":"2023041909290491300_b95","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jnnp.59.1.38","article-title":"Multifocal motor neuropathy with conduction block: a study of 24 patients","volume":"59","author":"Bouche","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909290491300_b96","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1600-0404.2007.00970.x","article-title":"No benefit of treatment with cyclophosphamide and autologous blood stem cell transplantation in multifocal motor neuropathy","volume":"117","author":"Axelson","year":"2008","journal-title":"Acta Neurol Scand"},{"key":"2023041909290491300_b97","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/WNL.31.11.1480","article-title":"The prevalence of monoclonal protein in peripheral neuropathy","volume":"31","author":"Kelly","year":"1981","journal-title":"Neurology"},{"key":"2023041909290491300_b98","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/archneur.1963.00460110102011","article-title":"Neurologic complications of myelomatosis","volume":"9","author":"Silverstein","year":"1963","journal-title":"Arch Neurol"},{"key":"2023041909290491300_b99","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/jcp.33.7.617","article-title":"Paraproteinaemia in neurological disease: incidence, associations and classification of monoclonal immunoglobulins","volume":"33","author":"Kahn","year":"1980","journal-title":"J Clin Pathol"},{"key":"2023041909290491300_b100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0022-510X(93)90297-C","article-title":"Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies","volume":"114","author":"Vrethem","year":"1993","journal-title":"J Neurol Sci"},{"key":"2023041909290491300_b101","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2141.1982.tb02816.x","article-title":"Benign monoclonal gammopathy and peripheral neuropathy","volume":"51","author":"Osby","year":"1982","journal-title":"Br J Haematol"},{"key":"2023041909290491300_b102","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jneuroim.2007.10.025","article-title":"Induction of experimental ataxic sensory neuronopathy in cats by immunization with purified SGPG","volume":"193","author":"Ilyas","year":"2008","journal-title":"J Neuroimmunol"},{"key":"2023041909290491300_b103","first-page":"CD005376","article-title":"Treatment for IgG and IgA paraproteinaemic neuropathy","author":"Allen","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2023041909290491300_b104","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jns.2007.04.022","article-title":"Cytogenetic aberrations in neuropathy associated with IgM monoclonal gammopathy","volume":"260","author":"Eurelings","year":"2007","journal-title":"J Neurol Sci"},{"key":"2023041909290491300_b105","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/brain\/117.5.941","article-title":"Distal accentuation of conduction slowing in polyneuropathy associated with antibodies to myelin-associated glycoprotein and sulphated glucoronyl paraglobiside","volume":"117","author":"Kaku","year":"1994","journal-title":"Brain"},{"key":"2023041909290491300_b106","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1212\/WNL.54.3.615","article-title":"Distal acquired demyelinating symmetric neuropathy","volume":"54","author":"Katz","year":"2000","journal-title":"Neurology"},{"key":"2023041909290491300_b107","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1093\/brain\/124.10.1968","article-title":"The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies","volume":"124","author":"Willison","year":"2001","journal-title":"Brain"},{"key":"2023041909290491300_b108","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/mus.880160113","article-title":"Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance","volume":"16","author":"Simmons","year":"1993","journal-title":"Muscle Nerve"},{"key":"2023041909290491300_b109","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/clinchem\/34.11.2196","article-title":"Strategy to diagnose monoclonal gammopathies in serum: high resolution electrophoresis, immunofixation, and kappa\/lambda quantification","volume":"34","author":"Keren","year":"1988","journal-title":"Clin Chem"},{"key":"2023041909290491300_b110","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/(SICI)1097-4598(200002)23:2<164::AID-MUS4>3.0.CO;2-Y","article-title":"Long-term clinical and neurophysiological follow-up of patients with peripheral, neuropathy associated with benign monoclonal gammopathy [see comments]","volume":"23","author":"Ponsford","year":"2000","journal-title":"Muscle and Nerve"},{"key":"2023041909290491300_b111","first-page":"CD002827","article-title":"Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies","author":"Lunn","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2023041909290491300_b112","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1212\/WNL.47.5.1227","article-title":"Intermittent cyclophosphamide and prednisone treatment of polyneuropathy associated with monoclonal gammopathy of undetermined significance","volume":"47","author":"Notermans","year":"1996","journal-title":"Neurology"},{"key":"2023041909290491300_b113","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1212\/01.wnl.0000265055.28218.cc","article-title":"Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy","volume":"69","author":"Niermeijer","year":"2007","journal-title":"Neurology"},{"key":"2023041909290491300_b114","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/jnnp.66.5.575","article-title":"Successful treatment of IgM paraproteinaemic neuropathy with fludarabine","volume":"66","author":"Wilson","year":"1999","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909290491300_b115","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1212\/01.wnl.0000247671.58066.21","article-title":"Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy","volume":"67","author":"Niermeijer","year":"2006","journal-title":"Neurology"},{"key":"2023041909290491300_b116","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/jnnp.69.2.279","article-title":"A randomized double-blind trial versus placebo do not confirm the efficacy of alpha-interferon in polyneuropathy associated with anti-MAG IgM monoclonal gammopathy","volume":"69","author":"Mariette","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2023041909290491300_b117","first-page":"979","article-title":"Neuropathies associated with IgG and IgA monoclonal gammopathy","volume":"158","author":"Nobile-Orazio","year":"2002","journal-title":"Rev Neurol (Paris)"},{"key":"2023041909290491300_b118","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1056\/NEJM199111213252105","article-title":"Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance","volume":"325","author":"Dyck","year":"1991","journal-title":"New Engl J Med"},{"key":"2023041909290491300_b119","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/art.1780370206","article-title":"Nomenclature of systemic vasculitides. Proposal of an international consensus conference","volume":"37","author":"Jennette","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2023041909290491300_b120","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1002\/art.1780330802","article-title":"The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction","volume":"33","author":"Hunder","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2023041909290491300_b121","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/39057","article-title":"Transmissions to mice indicate that \u201cnew variant\u201d CJD is caused by the BSE agent","volume":"389","author":"Bruce","year":"1997","journal-title":"Nature"},{"issue":"(Pt 4)","key":"2023041909290491300_b122","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/brain\/110.4.843","article-title":"Nonsystemic vasculitic neuropathy","volume":"110","author":"Dyck","year":"1987","journal-title":"Brain"},{"key":"2023041909290491300_b123","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1212\/01.WNL.0000082715.48844.3E","article-title":"Nonsystemic vasculitic neuropathy: insights from a clinical cohort","volume":"61","author":"Collins","year":"2003","journal-title":"Neurology"},{"key":"2023041909290491300_b124","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4065\/70.4.337","article-title":"Neurologic manifestations of Churg\u2013Strauss syndrome","volume":"70","author":"Sehgal","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"2023041909290491300_b125","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/rheumatology\/27.4.258","article-title":"Clinical findings and prognosis of polyarteritis nodosa and Churg\u2013Strauss angiitis: a study in 165 patients","volume":"27","author":"Guillevin","year":"1988","journal-title":"Br J Rheumatol"},{"key":"2023041909290491300_b126","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005792-199901000-00003","article-title":"Churg\u2013Strauss syndrome. Clinical study and long-term follow-up of 96 patients","volume":"78","author":"Guillevin","year":"1999","journal-title":"Medicine (Baltimore)"},{"key":"2023041909290491300_b127","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/qjmed\/hci015","article-title":"Primary systemic vasculitis: clinical features and mortality","volume":"98","author":"Lane","year":"2005","journal-title":"QJM"},{"key":"2023041909290491300_b128","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00415-005-0833-9","article-title":"Primary and secondary vasculitic neuropathy","volume":"252","author":"Said","year":"2005","journal-title":"J Neurol"},{"key":"2023041909290491300_b129","first-page":"391","article-title":"High prevalence of peripheral neuropathy in hepatitis C virus infected patients with symptomatic and asymptomatic cryoglobulinaemia","volume":"30","author":"Zaltron","year":"1998","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"2023041909290491300_b130","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1002\/1529-0131(199912)42:12<2507::AID-ANR2>3.0.CO;2-#","article-title":"Cryoglobulinemic vasculitis","volume":"42","author":"Lamprecht","year":"1999","journal-title":"Arthritis Rheum"},{"key":"2023041909290491300_b131","first-page":"277","article-title":"Vasculitic neuropathy in HIV infection: a clinicopathological study","volume":"49","author":"Mahadevan","year":"2001","journal-title":"Neurol India"},{"key":"2023041909290491300_b132","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/qjmed\/hcl125","article-title":"Treatment of vasculitic peripheral neuropathy: a retrospective analysis of outcome","volume":"100","author":"Mathew","year":"2007","journal-title":"QJM"},{"key":"2023041909290491300_b133","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/ncpneuro0811","article-title":"Management of acute central retinal artery occlusion","volume":"4","author":"Chen","year":"2008","journal-title":"Nat Clin Pract Neurol"},{"key":"2023041909290491300_b134","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/0961203307084172","article-title":"Systemic lupus erythematosus complicated with aortitis","volume":"17","author":"Breynaert","year":"2008","journal-title":"Lupus"},{"key":"2023041909290491300_b135","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S0002-9343(99)00424-6","article-title":"Positron emission tomography in giant cell arteritis and polymyalgia rheumatica: evidence for inflammation of the aortic arch","volume":"108","author":"Blockmans","year":"2000","journal-title":"Am J Med"},{"key":"2023041909290491300_b136","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10067-004-0998-0","article-title":"p-ANCA-associated periaortitis with histological proof of Wegener\u2019s granulomatosis: case report","volume":"24","author":"Carels","year":"2005","journal-title":"Clin Rheumatol"},{"key":"2023041909290491300_b137","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/ana.410230506","article-title":"The peripheral neuropathy of necrotizing arteritis: a clinicopathological study","volume":"23","author":"Said","year":"1988","journal-title":"Ann Neurol"},{"key":"2023041909290491300_b138","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1212\/WNL.55.5.636","article-title":"Superficial peroneal nerve\/peroneus brevis muscle biopsy in vasculitic neuropathy","volume":"55","author":"Collins","year":"2000","journal-title":"Neurology"},{"key":"2023041909290491300_b139","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ncl.2006.11.002","article-title":"Vasculitic neuropathies","volume":"25","author":"Burns","year":"2007","journal-title":"Neurol Clin"},{"key":"2023041909290491300_b140","first-page":"CD006050","article-title":"Immunosuppressive treatment for non-systemic vasculitic neuropathy","author":"Vrancken","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"2023041909290491300_b141","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa020286","article-title":"A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies","volume":"349","author":"Jayne","year":"2003","journal-title":"N Engl J Med"},{"key":"2023041909290491300_b142","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00005792-199509000-00002","article-title":"Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients","volume":"74","author":"Guillevin","year":"1995","journal-title":"Medicine (Baltimore)"},{"key":"2023041909290491300_b143","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/(SICI)1097-4598(199811)21:11<1526::AID-MUS23>3.0.CO;2-X","article-title":"Treatment of mononeuropathy multiplex in hepatitis C virus and cryoglobulinemia","volume":"21","author":"Scelsa","year":"1998","journal-title":"Muscle Nerve"},{"key":"2023041909290491300_b144","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1002\/art.10699","article-title":"Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis","volume":"46","author":"Cacoub","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2023041909290491300_b145","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1164\/rccm.200507-1144OC","article-title":"Rituximab for refractory Wegener\u2019s granulomatosis: report of a prospective, open-label pilot trial","volume":"173","author":"Keogh","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2023041909290491300_b146","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2002-10-3162","article-title":"Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20","volume":"101","author":"Sansonno","year":"2003","journal-title":"Blood"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/85\/1006\/437\/50020321\/postgradmedj-85-437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/85\/1006\/437\/50020321\/postgradmedj-85-437.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T09:40:03Z","timestamp":1681897203000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/85\/1006\/437\/7007264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,23]]},"references-count":146,"journal-issue":{"issue":"1006","published-online":{"date-parts":[[2009,7,23]]},"published-print":{"date-parts":[[2009,8,1]]}},"URL":"https:\/\/doi.org\/10.1136\/jnnp.2008.158303","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2009,8]]},"published":{"date-parts":[[2009,7,23]]}}}